ERBB2 and gastroesophageal junction adenocarcinoma: Between September 2016 and December 2019, 16 patients with HER2-negative gastric/GEJ adenocarcinoma were enrolled (six patients in the SP combination cohort [cohort 2], and 10 patients in the SOX combination cohort [cohort 3]) (Fig. S3).